Fujirebio submits FDA regulatory filing for Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test
Expected to be first commercially-available blood-based invitro diagnostic for patients being assessed for Alzheimer’s disease in the US